1. Search Result
Search Result
Results for "

influenza B

" in MedChemExpress (MCE) Product Catalog:

79

Inhibitors & Agonists

1

Screening Libraries

5

Peptides

1

Inhibitory Antibodies

7

Natural
Products

47

Recombinant Proteins

13

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-112543

    Influenza Virus Infection
    S119-8 is a broad spectrum inhibitor of influenza A and B viruses, showing activity against multiple influenza B viruses and an oseltamivir-resistant influenza A virus, but does not inhibit a non-influenza virus, vesicular stomatitis nirus (VSV) .
    S119-8
  • HY-143752

    Influenza Virus Infection
    Cap-dependent endonuclease-IN-8 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-8 inhibits replication of orthomyxoviruses (including influenza A, influenza B and influenza C) (extracted from patent CN111410661A, compound I-196) .
    Cap-dependent endonuclease-IN-8
  • HY-W892911

    Influenza Virus Infection
    AV-5080 is an orally active neuraminidase inhibitor. AV-5080 can be used for the research of influenza A and B viruses .
    AV-5080
  • HY-14837

    Enisamium iodide

    Influenza Virus SARS-CoV Infection
    Amizon (Enisamium iodide) is a broad-spectrum antiviral agent for influenza A and B. Amizon is an inhibitor for SARS-CoV-2 RNA polymerase .
    Amizon
  • HY-163659

    Influenza Virus Infection
    Anti-Influenza agent 6 (compound 19b) shows inhibitory activity against A/WSN/33/H1N1 (EC50 = 0.015 μM) and influenza B virus Yamagata/16/88 (EC50 = 0.073 μM) and Victotis/2/87 (EC50 = 0.067 μM) .
    Anti-Influenza agent 6
  • HY-P10593

    Transmembrane Glycoprotein Influenza Virus Cancer
    Influenza A NP (383-391) (HLA-B27) is a peptide sequence derived from tetanus toxin. Influenza A NP (383-391) (HLA-B27) is a broadly immunogenic CD4+ T helper cell epitope that enhances CD8+ cytotoxic T lymphocyte (CTL) responses. Influenza A NP (383-391) (HLA-B27) can be used in breast cancer research .
    Influenza A NP (383-391) (HLA-B27)
  • HY-143744

    Influenza Virus Infection
    Cap-dependent endonuclease-IN-3 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-3 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo agent kinetic properties and in vivo pharmacodynamic properties. Cap-dependent endonuclease-IN-3 has the potential for the research of influenza A and influenza B infection (extracted from patent WO2019141179A1, compound VI-1) .
    Cap-dependent endonuclease-IN-3
  • HY-143750

    Influenza Virus Infection
    Cap-dependent endonuclease-IN-7 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-7 Inhibits the synthesis of viral mRNA and eventually inhibits virus proliferation. Cap-dependent endonuclease-IN-7 has the potential for the research of viral infections (including influenza A, influenza B and influenza C) (extracted from patent WO2020177715A1, compound 5)
    Cap-dependent endonuclease-IN-7
  • HY-143781

    Influenza Virus Infection
    Cap-dependent endonuclease-IN-26 is a cap-dependent endonuclease (CEN) inhibitor with an IC50 of 286 nM. Cap-dependent endonuclease-IN-26 shows antiviral activity against many influenza A and B strains .
    Cap-dependent endonuclease-IN-26
  • HY-149050

    Influenza Virus SARS-CoV Infection
    Viral polymerase-IN-1 hydrochloride, a Gemcitabine (HY-17026) derivative, potently inhibits influenza A and B viruses infection with IC90 values of 11.4-15.9 μM. Viral polymerase-IN-1 hydrochloride is active against SARS-CoV-2 infection. Viral polymerase-IN-1 hydrochloride suppresses influenza virus infection by affecting viral RNA replication/transcription in cells .
    Viral polymerase-IN-1 hydrochloride
  • HY-W011518

    Influenza Virus Infection
    2′-Deoxy-2′-fluoroguanosine, a nucleoside analog, is a potent inhibitor of influenza virus strains, with an EC90 of <0.35 μM for influenza virus A and B strains. 2′-Deoxy-2′-fluoroguanosine significantly inhibits replication of influenza virus in the upper respiratory tract, resulting in amelioration of fever and nasal inflammation .
    2′-Deoxy-2′-fluoroguanosine
  • HY-113512

    Influenza Virus Inflammation/Immunology
    17-HDHA is a DHA-derived specialized proresolving mediator (SPM). 17-HDHA enhances the antibody-mediated immune response against influenza virus. 17-HDHA enhances the differentiation of B cells toward the CD27 + CD38 + antibody-secreting cell phenotype, thereby strongly increasing IgM and IgG production by activated B cells .
    17-HDHA
  • HY-162242

    Influenza Virus Infection
    Cap-dependent endonuclease-IN-27 (Compound 8) is an orally active potent cap-dependent endonuclease (CEN) inhibitor. Cap-dependent endonuclease-IN-27, an antiviral agent, shows activity against influenza B virus. Cap-dependent endonuclease-IN-27 has inhibitory activity against IFV A/WSN/33 (H1N1) polymerase (EC50 = 12.26 nM) .
    Cap-dependent endonuclease-IN-27
  • HY-13210
    Zanamivir
    10+ Cited Publications

    Influenza Virus Antibiotic Infection
    Zanamivir is an influenza viral neuraminidase inhibitor with IC50 values of 0.95 nM and 2.7 nM for influenza A and B, respectively.
    Zanamivir
  • HY-146004

    Influenza Virus Infection
    Influenza A virus-IN-4 (compound 23b), an Oseltamivir derivative, is a potent inhibitor of neuraminidase. Influenza A virus-IN-4 exerts powerful inhibitions on influenza viruses .
    Influenza A virus-IN-4
  • HY-168510

    Influenza Virus Infection
    ATV03 is an anti-influenza virus agent with excellent anti-influenza A and B virus activity. ATV03 inhibits anti-influenza A (H3N2) and anti-influenza B with EC50 values of 0.78 nM and 2.02 nM, respectively. ATV03 exerts anti-influenza activity by inhibiting polymerase acidic protein (PA) and RNA-dependent RNA polymerase (RdRp), as well as disrupting nuclear protein .
    ATV03
  • HY-B1537

    2',3',5'-Tri-O-acetyl-6-azauridine

    Virus Protease Influenza Virus Infection Inflammation/Immunology
    Azaribine (2',3',5'-Tri-O-acetyl-6-azauridine) is a potent orotidine monophosphate decarboxylase (OMPD) inhibitor. Azaribine is an antiviral inhibitor of several RNA viruses and inhibits viral genome replication and gene transcription. Azaribine shows broad-spectrum antiviral activity (EC50=3.80 nM-1.73 μM against influenza A and B viruses; EC50=1.62 μM against ZIKV Paraiba). Azaribine, a triacetate salt of Azauridine, has the potential for psoriasis research .
    Azaribine
  • HY-13210A

    Antibiotic Influenza Virus Infection
    Zanamivir hydrate (5:1) is the hydrate of Zanamivir. Zanamivir is an influenza viral neuraminidase inhibitor with IC50 values of 0.95 nM and 2.7 nM for influenza A and B, respectively .
    Zanamivir (hydrate)(5:1)
  • HY-P1857

    Influenza Virus Infection
    CEF7, Influenza Virus NP (380-388) is a HLA-B *08 restricted influenza virus nucleoprotein epitope. Influenza virus NP functions as a key adapter molecule between virus and host cell processes .
    CEF7, Influenza Virus NP (380-388)
  • HY-170646

    Influenza Virus Infection
    Influenza A virus-IN-15 (Compound 9b), a quinoline derivative, is a broad-spectrum inhibitor of influenza A viruses with acceptable cytotoxicity (IC50: 0.88-6.33 μM). Influenza A virus-IN-15 can inhibit the transcription and replication of viral RNA and is used in research for its antiviral effects against influenza A viruses (IAV) .
    Influenza A virus-IN-15
  • HY-109025
    Baloxavir marboxil
    5+ Cited Publications

    S-033188; RG 6152

    Influenza Virus Infection Cancer
    Baloxavir marboxil (S-033188) is a selective inhibitor of influenza cap-dependent endonuclease. Baloxavir marboxil, a potent antiviral agent, shows activity against influenza A and B virus .
    Baloxavir marboxil
  • HY-135646

    Influenza Virus Infection Inflammation/Immunology
    Eleutheroside B1, a coumarin compound, has a wide spectrum of anti-human influenza virus efficacy, with an IC50 value of 64-125 µg/ml. Eleutheroside B1 mediates its anti-influenza activity through POLR2A and N-glycosylation. Eleutheroside B1 inhibits the mRNA expression of several chemokine genes and the influenza nucleoprotein (NP) gene, and exhibits low cytotoxicity. Antiviral and anti-inflammatory activities .
    Eleutheroside B1
  • HY-17016
    Oseltamivir phosphate
    30+ Cited Publications

    GS 4104 phosphate

    Influenza Virus Infection Cancer
    Oseltamivir phosphate (GS 4104) is a neuraminidase inhibitor recommended for the treatment and prophylaxis of influenza A and B.
    Oseltamivir phosphate
  • HY-132286

    Protein Arginine Deiminase Infection
    2-PADQZ is an antiviral compound with activity against influenza viruses. 2-PADQZ specifically binds to the influenza A virus RNA promoter and forms a binding site at the internal loop. 2-PADQZ has a significant inhibitory effect on H1N1 and H3N2 influenza A viruses and influenza B viruses .
    2-PADQZ
  • HY-155110

    Influenza Virus Infection
    Antiviral agent 34 is a potent and orally active antiviral agent against influenza A and B subtypes with an EC50 value of 0.8 nM for H1N1 proliferation. Antiviral agent 34 derivatives inhibited influenza virus proliferation by targeting influenza virus RNA-dependent RNA polymerase. Antiviral agent 34 can be used for influenza virus research .
    Antiviral agent 34
  • HY-13210R

    Influenza Virus Antibiotic Infection
    Zanamivir (Standard) is the analytical standard of Zanamivir. This product is intended for research and analytical applications. Zanamivir is an influenza viral neuraminidase inhibitor with IC50 values of 0.95 nM and 2.7 nM for influenza A and B, respectively.
    Zanamivir (Standard)
  • HY-P1835

    Influenza Virus Inflammation/Immunology
    CEF8, Influenza Virus NP (383-391), an influenza A virus nucleoprotein containing residues 383 to 391, is the most important HLA-B *2705-restricted epitope in the nucleoprotein of influenza A viruses and is associated with escape from cytotoxic T lymphocytes-mediated immunity .
    CEF8, Influenza Virus NP (383-391)
  • HY-123716

    Antibiotic Bacterial Infection
    Rubradirin B is an antibiotic, which inhibits a variety of Gram-positive bacteria and Haemophilus influenza. Rubradirin B affects the ribosome functions .
    Rubradirin B
  • HY-13318
    Oseltamivir acid
    Maximum Cited Publications
    59 Publications Verification

    GS 4071; Ro 64-0802; Oseltamivir carboxylate

    Influenza Virus Drug Metabolite Infection
    Oseltamivir acid (GS 4071), the active metabolite of Oseltamivir phosphate, is an orally bioavailable, potent and selective inhibitor of influenza virus neuraminidase (IC50=2 nM) with activity against both influenza A and B viruses .
    Oseltamivir acid
  • HY-112684

    Influenza Virus Infection
    RO-7 is a next-generation polymerase (PA) endonuclease inhibitor of influenza A and B viruses.
    RO-7
  • HY-P99699

    MHAB5553A; RG70026

    Influenza Virus Infection
    Lesofavumab (MHAB5553A) is a human IgG1κ anti-influenza B virus antibody .
    Lesofavumab
  • HY-43575

    Influenza Virus Infection
    Oseltamivir-acetate is an impurity of Oseltamivir. Oseltamivir is a neuraminidase inhibitor recommended for the treatment and prophylaxis of influenza A and B .
    Oseltamivir-acetate
  • HY-144066

    Influenza Virus Infection
    Cap-dependent endonuclease-IN-21 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-21 inhibits the replication of influenza virus. ap-dependent endonuclease-IN-21 has the potential for the research of influenza virus infection (influenza A) (extracted from patent WO2021233302A1, compound 8B or 8A) .
    Cap-dependent endonuclease-IN-21
  • HY-144067

    Influenza Virus Infection
    Cap-dependent endonuclease-IN-23 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-23 inhibits the replication of influenza virus. ap-dependent endonuclease-IN-23 has the potential for the research of influenza virus infection (influenza A) (extracted from patent WO2021233302A1, compound 8A or 8B) .
    Cap-dependent endonuclease-IN-23
  • HY-17016S

    GS 4104-d5 phosphate

    Isotope-Labeled Compounds Influenza Virus Infection
    Oseltamivir-d5 (phosphate) is the deuterium labeled Oseltamivir phosphate. Oseltamivir phosphate (GS 4104) is a neuraminidase inhibitor recommended for the treatment and prophylaxis of influenza A and B[1][2].
    Oseltamivir-d5 phosphate
  • HY-105395

    Influenza Virus Infection
    BCX-1898, a cyclopentane derivative, is an orally active and selective influenza virus neuraminidase inhibitor. BCX-1898 has antiviral activity with EC50s of <0.01-21 μM on influenza A (H1N1, H3N2, and H5N1) and influenza B viruses replication in MDCK cells. BCX-1898 shows protection against the mouse influenza model .
    BCX-1898
  • HY-117151

    Influenza Virus Inflammation/Immunology
    A-315675 is a potent highly potent inhibitor of A and B strain influenza virus neuraminidases inhibitor .
    A-315675
  • HY-13317S

    Influenza Virus Infection
    Oseltamivir-d3 is a deuterium labeled Oseltamivir. Oseltamivir is an influenza virus neuraminidase inhibitor (NAI). Oseltamivir inhibits influenza A/H3N2, A/H1N2, A/H1N1, and B viruses with mean IC50s of 0.67, 0.9, 1.34 and 13 nM, respectively. Anti-influenza A and B agent[1].
    Oseltamivir-d3
  • HY-13317S3

    Influenza Virus Infection
    Oseltamivir-d5 is the deuterium labeled Oseltamivir[1]. Oseltamivir is an influenza virus neuraminidase inhibitor (NAI). Oseltamivir inhibits influenza A/H3N2, A/H1N2, A/H1N1, and B viruses with mean IC50 of 0.67, 0.9, 1.34 and 13 nM, respectively. Anti-influenza A and B agent[2].
    Oseltamivir-d5
  • HY-13317S4

    Isotope-Labeled Compounds Infection
    Oseltamivir-d3 hydrochloride is the deuterium-labeled Oseltamivir (HY-13317) . Oseltamivir is an influenza virus neuraminidase inhibitor (NAI). Oseltamivir inhibits influenza A/H3N2, A/H1N2, A/H1N1, and B viruses with mean IC50s of 0.67, 0.9, 1.34 and 13 nM, respectively. Anti-influenza A and B agent .
    Oseltamivir-d3 hydrochloride
  • HY-13317S1

    Influenza Virus Infection
    Oseltamivir-d3-1 is the deuterium labeled Oseltamivir[1]. Oseltamivir is an influenza virus neuraminidase inhibitor (NAI). Oseltamivir inhibits influenza A/H3N2, A/H1N2, A/H1N1, and B viruses with mean IC50s of 0.67, 0.9, 1.34 and 13 nM, respectively. Anti-influenza A and B agent[2].
    Oseltamivir-d3-1
  • HY-13318S
    Oseltamivir acid-d3
    Maximum Cited Publications
    59 Publications Verification

    GS 4071-d3; Ro 64-0802-d3; Oseltamivir carboxylate-d3

    Influenza Virus Infection
    Oseltamivir acid-d3 is a deuterium labeled Oseltamivir acid. Oseltamivir acid, the active metabolite of Oseltamivir phosphate, is an orally bioavailable, potent and selective inhibitor of influenza virus neuraminidase (IC50=2 nM) with activity against both influenza A and B viruses[1][2].
    Oseltamivir acid-d3
  • HY-143757

    Influenza Virus Infection
    Cap-dependent endonuclease-IN-10 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-10 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo pharmacokinetic and in vivo pharmacodynamic properties, and better hepatic microsomal stability. Cap-dependent endonuclease-IN-10 has the potential for the research of viral infections (including influenza A, influenza B and influenza C) (extracted from patent WO2021129799A1, compound 1-1) .
    Cap-dependent endonuclease-IN-10
  • HY-122261

    DU-34569 maleate

    Influenza Virus Infection
    Spiroamantadine (DU-34569 maleate) is a compound related to Amantadine (HY-B0402) with anti-influenza virus activity .
    Spiroamantadine
  • HY-14818B

    R 125489 TFA

    Influenza Virus Infection
    Laninamivir TFA (R 125489 TFA) is an antiviral compound with inhibitory and prophylactic activity against influenza A and B viruses. Laninamivir TFA is a long-acting neuraminidase inhibitor administered by nasal inhalation. Laninamivir TFA has shown good safety and efficacy in the inhibition of influenza viruses .
    Laninamivir TFA
  • HY-109025R

    Influenza Virus Infection
    Baloxavir marboxil (Standard) is the analytical standard of Baloxavir marboxil. This product is intended for research and analytical applications. Baloxavir marboxil (S-033188) is a selective inhibitor of influenza cap-dependent endonuclease. Baloxavir marboxil, a potent antiviral agent, shows activity against influenza A and B virus .
    Baloxavir marboxil (Standard)
  • HY-13318R

    Influenza Virus Drug Metabolite Infection
    Oseltamivir acid (Standard) is the analytical standard of Oseltamivir acid. This product is intended for research and analytical applications. Oseltamivir acid (GS 4071), the active metabolite of Oseltamivir phosphate, is an orally bioavailable, potent and selective inhibitor of influenza virus neuraminidase (IC50=2 nM) with activity against both influenza A and B viruses .
    Oseltamivir acid (Standard)
  • HY-B2226
    Sodium copper chlorophyllin B
    1 Publications Verification

    HIV Influenza Virus Infection
    Sodium copper chlorophyllin B exerts antiviral activities against Influenza virus and HIV with IC50s of 50 to 100 μM for both of them.
    Sodium copper chlorophyllin B
  • HY-17016S1

    GS 4104-d3 phosphate

    Isotope-Labeled Compounds Influenza Virus Infection
    Oseltamivir-d3 (phosphate)eis the deuterium labeled Oseltamivir phosphate. Oseltamivir phosphate (GS 4104) is a neuraminidase inhibitor recommended for the treatment and prophylaxis of influenza A and B.
    Oseltamivir-d3 phosphate
  • HY-17016R

    GS 4104 (phosphate) (Standard)

    Influenza Virus Infection
    Oseltamivir (phosphate) (Standard) is the analytical standard of Oseltamivir (phosphate). This product is intended for research and analytical applications. Oseltamivir phosphate (GS 4104) is a neuraminidase inhibitor recommended for the treatment and prophylaxis of influenza A and B.
    Oseltamivir (phosphate) (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: